Alpharadin (radium-223)

///Alpharadin (radium-223)

Repeating Treatment with Radium-223 (Xofigo) is Safe and Effective

Radium-223 (Xofigo) is a drug for men with castrate resistant metastatic prostate cancer (mCRCP) who have multiple bone metastases. Radium-223 selectively targets bone metastases by mimicking calcium, which is attracted to the bone, especially to the fast growing areas of the tumor in the bone. It emits an alpha-emitting dose of radiation, which is mostly contained in the tumor due to the low spread of alpha waves).

The current FDA approval for Radium-223 is for one course of 6 injections. Men have been asking if it is possible to have a re-treatment of Radium-223 once the disease has progressed after having had […]

Not All Men Benefit From Radium-223 (Xofigo)?

Researchers are now beginning to understand which men with castration-resistant prostate cancer (CRPC) might be helped by radium-223 (Xofigo), and for which men Xofigo will be a waste of time and money, and possibly cause harm.

They have found that baseline ECOG performance status, alkaline phosphatase (ALP), hemoglobin (Hb) levels, and the concomitant use of abiraterone acetate (Zytiga) or denosumab were indicators for improved overall survival (OS) when radium-223 is used. These findings came from a phase IIIb follow-up to the pivotal phase III ALSYMPCA trial presented at the 7th European Multidisciplinary Meeting on Urological Cancers (EMUC).

Data from the post-hoc analysis showed an improved […]

Chemotherapy After Radium-223 Appears to be Safe in Men with Metastatic Castration-Resistant Prostate Cancer

 

Understanding how to best sequence and combine our new drugs to treat advanced prostate cancer includes the most discussed issue, efficacy. We want to know if a special order or a special combination of the approved drugs will nake a difference in both our quality of life (QoL) as well as how survival. Often left out of this conversation is safety, will the order we take our drugs or in what combination affect the our safety? We know that many of our new drugs cause cross-resistance to the next drug, however we rarely ask about the potential toxic effects that […]

Radium-223 When Given In Combinations May Improve Survival in mCRPC

As I have said before, the next big step in the clinical care of men with prostate cancer will be in not in the development of a new drug, but in our growing knowledge of how to sequence and combine our new drugs. Today’s post provides just one example of this new type of breakthrough we can look forward to in the near future.

In a recently released phase IIIb study of Radium-223 dichloride (Xofigo) that was given with concomitant medication, there was an improvement in overall survival (OS) in men with metastatic castration-resistant prostate cancer (mCRPC) who also had bone […]